Linked Life Data

10481552

Source:http://linkedlifedata.com/resource/pubmed/id/10481552

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
36
pubmed:dateCreated
1999-10-21
pubmed:abstractText
The vaccine against Lyme disease for last decade became an important issue for many researchers. Recently two groups of scientists published data of their trials carried out on humans. The vaccine which was given to volunteers consisted of recombinant outer surface protein (Osp)A. These people were observed for two years when approximately 79% of them developed resistance to Borrelia burgdorferi infection. These data were evaluated by FDA experts who recommended vaccine for approval. Main concerns of experts are: short duration of observation of vaccinated people, no possibility to vaccinate children, problematic vaccination people with undiagnosed Lyme disease. However the moment when effective and safe vaccine against Lyme disease will be available seems to approach.
pubmed:language
pol
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1426-9686
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
344-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
[Lyme disease vaccine: hopes and concerns].
pubmed:affiliation
Kliniki Chorób Pasozytniczych i Neuroinfekcji AM w Bia?ymstoku.
pubmed:publicationType
Journal Article, English Abstract